trial

Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

NCTId NCT02054702
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 97 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2014-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
97 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2014-02
Primary completion
2014-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)Aripiprazole

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Collaborator

Investigators

1
Jun-ichi Hashimoto, PhDStudy Director

Sites

0 total

Linked catalysts

1
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophre — primary completion2014-06

Facts & assertions

4 sourced
Enrollment
97
Phase
PHASE3
Primary Completion Date
2014-06
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
Aripiprazole
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Psychotic Disorders
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jun-ichi Hashimoto, PhD
person